Please login to the form below

Not currently logged in
Email:
Password:

BIIB059

This page shows the latest BIIB059 news and features for those working in and with pharma, biotech and healthcare.

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen has started dosing patients in a late-stage study evaluating its potential systemic lupus erythematosus (SLE) treatment BIIB059. ... added. In addition to BIIB059, Biogen also has another investigational lupus asset – dapirolizumab pegol –

Latest news

  • Biogen scores mid-stage trial win for lupus drug BIIB059 Biogen scores mid-stage trial win for lupus drug BIIB059

    The SLE arm only tested the highest 450mg dose of BIIB059, and showed the drug reduced the number of joints with active inflammation compared to placebo at 24 weeks. ... We are excited by the LILAC study results, and the potential for BIIB059 to be a

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...